Effects of Diet-induced Weight Loss in Obese Men
The Effects of Diet-induced Weight Loss on Metabolic and Inflammatory Profile, Endothelial, Sexual and Urinary Function, and Quality of Life in Obese Men
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 529889
- Changi General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, aged 30-65 years
- Body Mass Index (BMI) >/= 27.5 kg/m2
- Waist circumference (WC) >/= 90 cm
Exclusion Criteria:
- pituitary disease or cranial radiotherapy
- previous or current androgen replacement or deprivation therapy
- current treatment for sexual problems or LUTS
- glomerular filtration rate < 60 ml/min
- liver disease
- alcohol intake exceeding 500 g/week in the previous 12 months
- use of opiates, glucocorticoids, recreational drugs or phosphodiesterase inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: conventional diet counselling
counselling given by dietician on diet modification and caloric restriction
|
|
|
ACTIVE_COMPARATOR: partial meal replacement diet
calorie-restricted diet using 1-2 meal replacements
|
1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
erectile function
Time Frame: 12 weeks
|
increase in IIEF-5 score
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
lower urinary tract symptoms
Time Frame: 12 weeks
|
decrease in IPSS score
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Joan Khoo, MBBS,MRCP, Changi General Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2010075D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.